Pragmatic and Observational Research
Volume 12, 2021 - Issue
Study Protocol
Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes
David Price1 Observational and Pragmatic Research Institute, Singapore, Singapore;2 Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UKCorrespondence[email protected]
https://orcid.org/0000-0002-9728-9992View further author information
https://orcid.org/0000-0002-9728-9992View further author information, , Pascal Pfister4 Novartis Pharma AG, Basel, Switzerlandhttps://orcid.org/0000-0002-2276-5042View further author information
https://orcid.org/0000-0002-2276-5042View further author information, , , , Björn Holzhauer4 Novartis Pharma AG, Basel, Switzerlandhttps://orcid.org/0000-0002-9209-757XView further author information
https://orcid.org/0000-0002-9209-757XView further author information, , , David M G Halpin9 University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UKhttps://orcid.org/0000-0003-2009-4406View further author information
https://orcid.org/0000-0003-2009-4406View further author information, , , Job F M van Boven12 Department of Clinical Pharmacy & Pharmacology, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, the Netherlandshttps://orcid.org/0000-0003-2368-2262View further author information
https://orcid.org/0000-0003-2368-2262View further author information, , Konstantinos Kostikas14 Respiratory Medicine Department, University of Ioannina School of Medicine, Ioannina, Greecehttps://orcid.org/0000-0003-0774-3942View further author information
https://orcid.org/0000-0003-0774-3942View further author information, Nicolas Roche15 Cochin Hospital and Institute, APHP Centre, University of Paris, Paris, Francehttps://orcid.org/0000-0002-3162-5033View further author information
https://orcid.org/0000-0002-3162-5033View further author information, Omar Usmani16 National Heart & Lung Institute (NHLI), Imperial College London and Royal Brompton Hospital, London, UKhttps://orcid.org/0000-0002-4367-254XView further author information
https://orcid.org/0000-0002-4367-254XView further author information & Paul Mastoridis5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAhttps://orcid.org/0000-0003-0948-0066View further author information
https://orcid.org/0000-0003-0948-0066View further author information show all